Finerenone for IgA Nephropathy After Renin‐Angiotensin System Inhibitors Discontinuation: A Multicentre Retrospective Cohort Study

Diabetes Obes MetabPublished Retrospective cohort study

Authors' conclusion

Finerenone achieved short-term proteinuria reductions in RASi discontinued IgAN patients similar to those achieved with RASi monotherapy. Finerenone combined with RASi enhanced antiproteinuric efficacy while maintaining safety.

Study context

Population
Patients with primary IgA nephropathy, baseline estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m² and urinary total protein ≥ 0.5 g/daypropensity score matched
Participants
258 patients
Exposure
Finerenone plus renin-angiotensin system inhibitor (RASi) vs finerenone vs RASi
  • Finerenone plus RASin = 86
  • Finerenonen = 86
  • RASin = 86reference
Outcome
Percentage change in urinary total protein from baseline; rate of significant response (≥ 50% reduction in UTP and < 20% increase in serum creatinine)
Follow-up
12 months
Methodological detailsmulticentre, 1:1:1 propensity score matching
  • Multicentre
  • 1:1:1 propensity score matching

Main finding

As reported in the abstract

Percentage change in UTP from baseline

Finerenone plus RASi

54.43%

Finerenone

32.24%

RASi

34.35%

Finerenone vs RASi: P = 0.220 · Finerenone plus RASi vs Finerenone or RASi: both p < 0.01

Observational data: associations, not effects.

Further findings

Chronic eGFR slope

mL/min/1.73 m²/year

OutcomeFinerenone plus RASiFinerenoneRASi
Total eGFR decline−1.48−0.44−0.52

Total eGFR decline

Difference not statistically significant vs finerenone or RASi

Chronic eGFR slope

Difference not statistically significant vs finerenone or RASi

Safety

Incidence of adverse events comparable across all three groups

Original publication

Finerenone for IgA Nephropathy After Renin‐Angiotensin System Inhibitors Discontinuation: A Multicentre Retrospective Cohort Study. Diabetes Obes Metab. Published 17 August 2026. doi:10.1111/dom.71225

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.